Intravenous Infusions is trading 8.33% down at GHS 0.44 after continued profit-taking following its speculative rally to GHS 0.86 on July 30.
- Selling pressure has persisted through several consecutive declines.
- First-half revenue fell 39%, while margins improved and the company returned to profitability.
- Available coverage identifies no new August 13 announcement, making post-rally unwinding the clearest explanation.